Indeed, one human trial has recently reported that concurrent blockade of CTLA-4 and PD-1 was synergistic in generating anti-tumor responses in melanoma patients, while adverse immune-related toxicities were no more prevalent than with monotherapy [64]. Here, PDCD1 is linked to melanoma.